Stock A092730 NEOPHARM CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings NeoPharm CO., LTD.

Equities

A092730

KR7092730001

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 13/05/2024 BST 		5-day change 1st Jan Change
24,950 KRW -3.85% Intraday chart for NeoPharm CO., LTD. -1.77% -3.48%
2023 NeoPharm CO., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
2019 NeoPharm CO., LTD. announced that it has received KRW 31.970667276 billion in funding CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • The company is one of the most undervalued, with an "enterprise value to sales" ratio at 1624.97 for the 2024 fiscal year.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • The group usually releases upbeat results with huge surprise rates.

Ratings chart - Surperformance

Sector: Personal Products

1st Jan change Capi. Investor Rating ESG Refinitiv
NEOPHARM CO., LTD. Stock NeoPharm CO., LTD.
-3.48% 144M -
L'ORÉAL Stock L'Oréal
+1.14% 265B
B-
KAO CORPORATION Stock Kao Corporation
+20.31% 20.59B
B+
SHISEIDO COMPANY, LIMITED Stock Shiseido Company, Limited
+14.35% 12.22B
A-
COTY INC. Stock Coty Inc.
-12.64% 9.42B
A-
AMOREPACIFIC CORPORATION Stock Amorepacific Corporation
+16.55% 7.67B
B+
PROYA COSMETICS CO.,LTD. Stock Proya Cosmetics Co.,Ltd.
+11.43% 6.05B
B
NATURA &CO HOLDING S.A. Stock Natura &Co Holding S.A.
-2.43% 4.45B
B+
INTER PARFUMS, INC. Stock Inter Parfums, Inc.
-13.62% 3.98B
C-
INTERPARFUMS Stock Interparfums
-4.07% 3.66B
B-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
-
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. A092730 Stock
  4. Ratings NeoPharm CO., LTD.